Fig. 2

NNI-362 improves memory and increases adult-born neural cells in an aging mouse model (a–c) and a Down syndrome mouse model (d–f). Percent time spent with a novel object during acquisition and memory task, n = 8–11 (a). Number of BrdU-positive cells in the dentate gyrus of the hippocampus after 5–6 weeks oral treatment, n = 3 (b). Latency to fall from bridge test, n = 8–11 (c). Percent time spent with a novel object during memory task, n = 5–9 (d). Number of BrdU-positive cells in the dentate gyrus of the hippocampus after 4 weeks oral treatment, n = 2–4 (e). Distance traveled during an open field test, n = 9–14. BrdU staining and DS behavioral outcomes were analyzed using Kruskal-Wallis with group as factor. Behavioral measurements for the aging study were subjected to one-way ANOVA with group as factor. *p < 0.05 vs. young control; ^#p < 0.05 vs. old control; ^@p < 0.05 vs. WT-vehicle; ⁺p < 0.05 vs. DS-vehicle